Physician profile
Mark Schlosberg
NPI 1851326318
$7,927.17
in general payments reported to CMS, 2019-2025
38 companies · $2,546 in 2025
The $2,546 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $364 · 2021: $203 · 2022: $561 · 2023: $1,119 · 2024: $1,823 · 2025: $2,546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,488.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,708.92 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,277.86 | 2019-2025 | Ofev, Jascayd, Spiriva Respimat |
| Jazz Pharmaceuticals INC. | $694.25 | 2019-2025 | Xywav |
| Insmed, INC. | $527.20 | 2019-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $501.77 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $439.63 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $383.11 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $380.05 | 2019-2025 | |
| Verona Pharma, INC. | $203.72 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $199.97 | 2024-2025 | Sunosi |
| United Therapeutics Corporation | $193.91 | 2021-2025 | Tyvaso, Tyvaso, Remodulin |
| Merck Sharp & Dohme LLC | $193.49 | 2023-2025 | Winrevair |
| Amgen INC. | $175.01 | 2022-2024 | Tezspire |
| Pulmonx Corporation | $140.08 | 2023-2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Mallinckrodt Enterprises LLC | $115.61 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $95.41 | 2019-2023 | Yupelri |
| Mallinckrodt Hospital Products INC. | $86.00 | 2023-2025 | Acthar |
| Baxter Healthcare | $74.79 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| La Jolla Pharmaceutical Company | $50.61 | 2023-2024 | Giapreza |
| Genentech USA, INC. | $46.72 | 2019 | |
| Abbvie INC. | $45.98 | 2022-2023 | Teflaro |
| Csl Behring | $44.05 | 2022-2023 | Hizentra |
| Viatris Specialty LLC | $42.08 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $39.15 | 2023-2024 | Glassia |
| Actelion Pharmaceuticals US, INC. | $36.22 | 2025 | Opsumit, Uptravi |
| Nabriva Therapeutics, Plc | $27.42 | 2020 | |
| Ani Pharmaceuticals, INC. | $21.95 | 2023 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $21.85 | 2025 | Ultomiris |
| Vapotherm INC | $21.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.24 | 2019 | |
| Tactile Systems Technology INC | $19.29 | 2024 | Flexitouch Plus, Entre Plus |
| Allergan, INC. | $17.75 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $16.53 | 2025 | Lumryz |
| Teva Pharmaceuticals USA, INC. | $15.22 | 2022 | |
| Electromed, INC. | $14.11 | 2023 | Smartvest |
| Pfizer INC. | $13.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.71 | 2020 | |
| Inogen, INC. | $9.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schlosberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.